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Group A rotavirus (RVA) is the leading cause of acute gastroenteritis in young children worldwide. A
prospective surveillance network has been set up to investigate the virological and clinical features of
RVA infections and to detect the emergence of potentially epidemic strains in France. From 2009 to 2014,
RVA-positive stool samples were collected from 4800 children <5 years old attending the paediatric
emergency units of 16 large hospitals. Rotaviruses were then genotyped by RT-PCR with regard to their
outer capsid proteins VP4 and VP7. Genotyping of 4708 RVA showed that G1P[8] strains (62.2%) were
predominant. The incidence of G9P[8] (11.5%), G3P[8] (10.4%) and G2P[4] (6.6%) strains varied consid-
erably, whereas G4P[8] (2.7%) strains were circulating mostly locally. Of note, G12P[8] (1.6%) strains
emerged during the seasons 2011e12 and 2012e13 with 4.1% and 3.0% prevalence, respectively. Overall,
40 possible zoonotic reassortants, such as G6 (33.3%) and G8 (15.4%) strains, were detected, and were
mostly associated with P[6] (67.5%). Analysis of clinical records of 624 hospitalized children and severity
scores from 282 of them showed no difference in clinical manifestations or severity in relation to the
genotype. The relative stability of RVA genotypes currently co-circulating and the large predominance of
P[8] type strains may ensure vaccine effectiveness in France. The surveillance will continue to monitortional de Reference des virus enteriques, Laboratoire de Virologie, CHU de Dijon, 2 rue Angelique Ducoudray, BP 37013,
e.fr (A. de Rougemont).
biology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
A. de Rougemont et al. / Clinical Microbiology and Infection 22 (2016) 737.e9e737.e15737.e10the emergence of new reassortants that might not respond to current vaccines, all the more so as all
genotypes can cause severe infections in infants. A. de Rougemont, CMI 2016;22:737.e9e737.e15
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Group A rotavirus (RVA) is the leading cause of acute gastro-
enteritis in young children worldwide, and is estimated to cause
around 453 000 deaths every year in children <5 years old, mostly
in developing countries [1]. Although fast and appropriate care has
considerably reduced mortality in industrialized countries, rotavi-
ruses are still responsible for considerable morbidity in infants and
generate signiﬁcant health costs.
RVAs belong to the Reoviridae family and possess a genome
composed of 11 dsRNA genomic segments encoding six structural
(VPs) and ﬁve/six non-structural (NSPs) proteins. On the basis of the
outer capsid proteins VP7 and spikes VP4, RVAcan be classiﬁed intoG
and P genotypes, respectively. Nucleotide differences in these two
genes currently allow the classiﬁcation of RVA into 27 G genotypes
and 37 P genotypes, among which 12 G and 15 P are associated with
infections in humans, hence showing a considerable diversity of
strains [2,3]. Both viral outer layer proteins elicit the production of
neutralizing antibodies in the host, but no precise G or P type clearly
correlates with the severity of the disease. The ﬁve RVA genotype
combinations G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] are
responsible forapproximately 90%ofRVA infections in children [4].Of
note, uncommon G types such as G5, G8, G10 and G12 have emerged
in various areas of the world, notably in tropical regions [5,6].
Local data on the current burden of rotavirus disease, including
both virological and clinical aspects, are important for decision-
making and optimization regarding immunization strategies [7].
Hence, knowledge of the molecular epidemiology and antigenic di-
versity of co-circulating rotaviruses is necessary to ensure the suit-
ability and efﬁcacy of vaccines. Indeed, RVA diversity is constantly
generated by positive selection of single amino acid mutations in
deﬁned epitopes, and particularly in highly divergent regions of the
outer capsid protein VP7 [8]. Programmes to monitor rotavirus
antigenic drifts that might be caused by speciﬁc immunological
pressures and tomonitor potential reassortments betweenhumanor
human and animal strains have to be carefully developed.
In France, rotavirus infections occur mostly during the winter
and spring seasons. Although deaths remain exceptional, RVA are
responsible for about 300 000 acute diarrhoea episodes, half of
which are severe, 140 000 consultations and 18 000 hospitaliza-
tions each year [9]. In spite of the introduction of RVA vaccines in
2006, coverage remains particularly low in France and was esti-
mated at around 8.9% in French infants<12months old in 2011 [10].
Since the establishment of the French rotavirus surveillance
network by the National Reference Centre for Enteric Viruses (Di-
jon, France), it has become possible to assess the nationwide cir-
culation of RVA strains, especially in infants. This prospective study
was designed to monitor and characterize rotavirus infections,
including both viral and clinical data, in children <5 years old
suffering from community-acquired acute gastroenteritis and
attending paediatric emergency units during the rotavirus vaccine
era in France. Special attention was paid to the detection of un-
common strains and emerging reassortants.
Methods
After its approval by the local ethical committee (Comite Con-
sultatif de Protection des Personnes dans la Recherche Biomedicalede Bourgogne, Dijon, France, on 24 November 2005), the surveil-
lance study was conducted during ﬁve consecutive seasons from
July 2009 to June 2014, and involved 4800 children <5 years old
suffering from rotavirus-induced acute gastroenteritis and
attending the paediatric emergency units of 16 French Hospitals in
13 regions, including Paris.
Acute gastroenteritis was deﬁned by at least three soft or liquid
stools or three bouts of vomiting in 24 h. Children presenting with
chronic diarrhoea, immune deﬁciency, inﬂammatory disease of the
digestive tract, or nosocomial infections were excluded.
Clinical data, including personal identiﬁcation and clinical
symptoms, were collected from children presenting to paediatrics
departments. Informed consent was obtained for all participants.
Disease severity was calculated using the Vesikari scale, a 0e20
point numerical score that assesses the clinical severity of rotavirus
infections (where higher scores indicate greater severity), as pre-
viously described [11]. An episode of gastroenteritis with a score
11 is considered a severe episode.
The stool samples were routinely screened for RVA using mainly
immunochromatographic tests or enzyme immunoassays. All
rotavirus-positive samples were stored at e20C until genotyping
by the National Reference Centre for Enteric Viruses, University
Hospital of Dijon, France. The rotavirus strains were genotyped
using RT-PCR according to the EuroRotaNet methods (www.
eurorota.net/docs.php) and using the Qiagen OneStep RT-PCR kit
(Qiagen, Hilden, Germany). The VP7, VP4, VP6 and NSP4 PCR
products from strains of interest were sequenced with the same
primers as for ampliﬁcations. All the sequencing reactions were
performed using the ABI® PRISM® Terminator Cycle Sequencing Kit
on a 3130XL DNAGenetic Analyzer (Applied Biosystems, Foster City,
CA, USA). The nucleotide sequences were edited and genotyped
using BIONUMERICS software (Applied Maths NV, Sint-Martens-
Latem, Belgium) and a selection of sequences from rotavirus
reference strains available from the GenBank database. Phyloge-
netic analysis was performed using MEGA6 software [12]. After
sequence alignment using the MUSCLE program [13], a phyloge-
netic tree was inferred using the Maximum Likelihood method
based on the Tamura three-parameter model, which was the best-
ﬁt DNA substitution model for the nucleotide data set submitted.
Bootstrap values were calculated for 1000 replicates. The nucleo-
tide sequences of representative G12 strains from this study have
been deposited in the GenBank database (http://www.ncbi.nlm.
nih.gov/genbank/) under the following accession numbers:
KU291317 to KU291349.
Statistical analyses were performed using STATA® v11.0 software
from StataCorp (College Station, TX, USA). Comparisons of clinical
data and severity scores between G1 and G12 RVA, and between all
RVA genotypes were performed using the Fisher-exact test for
categorical data and the KruskaleWallis test for quantitative data.
Fractional polynomials were used to model the relationship be-
tween children’s ages and severity scores using a linear regression
model including a non-zero intercept. Values of p 0.05 were
considered signiﬁcant.
Results
From July 2009 to June 2014, 4800 stools specimens were
collected with a mean rate of 73.8 samples per centre and per
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of the year after). The mean and median ages of the young patients
were 13.7 and 10.5 months, respectively (range 0.2e59.9 months)
and the male/female ratio was 1.34. Most rotavirus infections
occurred in children <2 years old (83.9%). From the 4800 rotavirus-
positive stool samples, 92 (1.9%) could not be genotyped by RT-PCR,
and 4708 were successfully genotyped. Of these, 4578 (97.2%) faecal
specimens contained only one RVA strain, 64 (1.4%) were mixed
infections of G and P types, and 66 (1.4%) were partially genotyped.
RVA infections occurred in France throughout the year with a
peak between January and April (Fig. 1a). However, in most of the
provincial cities, RVA infections peaked 2 months later (i.e. be-
tween February andMarch) than in the largest cities in our network
(i.e. between January and February in Paris and Lyon) (Fig. 1b).
Molecular distribution of circulating rotavirus strains
G1 strains were the most predominant during the course of
the study and in most cities with a mean prevalence of 63.5%
(53.5%e73.8%). The four other major G genotypes (G2, G3, G4 and
G9) accounted for 34.0% (17.9%e44.7%) of infections with wide
individual amplitude according to the season (see Supplementary
material, Tables S1 and S2). Of note, G12 strains accounted for
1.7% (0.0%e3.3%). Mixed infections involved associations of G1
strains with one of the other major G genotypes in 75.5% (57.1%e
100.0%). In addition, the distribution of P genotypes showed a
clear predominance of P[8] strains with a mean detection rate of
91.2% (76.6%e97.9%) followed by P[4] strains with 8.0% (1.4%eFig. 1. Temporal and geographical distribution of rotavirus infections in France from July 20
in seven major centres. (b) Annual distribution of rotavirus infections per month of seven22.1). The study of the distribution of G genotype prevalence per
month showed that G2 and G9 RVA infections were more
frequently detected during the ﬁrst part of the epidemic season
(i.e. from September to January) whereas G3, G4, G12 and to a
lesser extent G1 RVA infections were more frequent during the
second part and at the peak of the epidemic (from January to
June) (see Supplementary material, Fig. S1a, b). Moreover, no
predominant RVA genotype was detected according to the age
group.
Distribution of the genotype combinations showed a clear pre-
dominance of G1P[8] strains (62.2%; 54.3%e73.1%) associated with
heterogeneous circulation of secondary major strains, i.e. G9P[8]
(11.5%; 7.3%e22.0%), G3P[8] (10.4%; 1.5%e19.3%), G2P[4] strains
(6.6%; 1.1%e17.5%) and G4P[8] (2.7%; 0.8%e7.3%), depending on
seasons (Table 1). The ﬁve major genotype combinations accounted
for 93.3% (92.3%e96.2%) of strains, showing a relatively stable
detection rate from season to season. Of note, G2P[4] strain circu-
lation rapidly decreased from 17.5% during the 2009e10 season to
reach 1.1% during the last season, whereas G9P[8] strains, which
remained stable at 8.9% (6.3%e11.5%) during the ﬁrst four seasons,
increased to 22.0% during the 2013e14 season. The circulation of
G3P[8] strains increased signiﬁcantly during the last three seasons
to reach a mean detection rate of 15.5% (13.2%e19.3%) (see
Supplementary material, Fig. S2) [35]. Combinations of major hu-
man RVA genotypes (i.e. P[4] with either G1, G3, G4 and G9; and P
[8] with G2) were regularly detected during the study with a mean
prevalence of 1.7% (0.6%e3.2%) but were decreasing over time
(Table 1).09 to June 2014. (a) Five-year cumulative distribution of rotavirus infections per month
major centres.
Table 1
Distribution and detection rates of G and P genotype combinations of group A rotavirus detected in France from 2009 to 2014
No. of strains detected during the ﬁve consecutive seasons (%) Total strains
(%)
2009e10 2010e11 2011e12 2012e13 2013e14 2009e2014
n¼812 n¼859 n¼849 n¼1095 n¼1093 n¼4708
Common strains 757 (93.2) 826 (96.2) 784 (92.3) 1011 (92.3) 1010 (92.4) 4388 (93.2)
G1P[8] 503 (61.9) 628 (73.1) 465 (54.8) 731 (66.8) 593 (54.3) 2920 (62.0)
G2P[4] 143 (17.5) 37 (4.3) 50 (5.9) 43 (3.9) 12 (1.1) 285 (6.1)
G3P[8] 12 (1.5) 35 (4.1) 164 (19.3) 144 (13.2) 153 (14.0) 508 (10.8)
G4P[8] 16 (2.0) 63 (7.3) 7 (0.8) 24 (2.2) 12 (1.1) 122 (2.6)
G9P[8] 83 (10.2) 63 (7.3) 98 (11.5) 69 (6.3) 240 (22.0) 553 (11.7)
Emerging strains
G12P[8] 0 3 (0.3) 35 (4.1) 33 (3.0) 7 (0.6) 78 (1.7)
Human reassortants 28 (3.2) 11 (1.3) 17 (2.0) 11 (1.0) 7 (0.6) 74 (1.6)
G1P[4] 5 (0.6) 4 (0.5) 4 (0.5) 0 0 13 (0.3)
G2P[8] 1 (0.1) 4 (0.5) 8 (0.9) 7 (0.6) 5 (0.5) 25 (0.5)
G3P[4] 21 (2.4) 1 (0.1) 1 (0.1) 0 1 (0.1) 24 (0.5)
G4P[4] 0 0 1 (0.1) 2 (0.2) 0 3 (0.1)
G9P[4] 1 (0.1) 2 (0.2) 3 (0.4) 2 (0.2) 1 (0.1) 9 (0.2)
Unusual strains 11 (1.4) 5 (0.6) 4 (0.5) 12 (1.1) 8 (0.7) 40 (0.8)
G1P[6] 1 (0.1) 0 0 5 (0.5) 0 6 (0.1)
G3P[3] 0 0 0 1 (0.1) 0 1 (<0.1)
G3P[6] 1 (0.1) 0 0 0 1 (0.1) 2 (<0.1)
G3/G9P[6] a 0 2 (0.2) 0 0 0 2 (<0.1)
G3P[9] 0 0 0 0 3 (0.3) 3 (0.1)
G4P[6] 2 (0.2) 0 0 0 0 2 (<0.1)
G6P[6] 1 (0.1) 1 (0.1) 2 (0.2) 2 (0.2) 4 (0.4) 10 (0.2)
G6P[14] 2 (0.2) 1 (0.1) 0 0 0 3 (0.1)
G8P[4] 1 (0.1) 0 0 0 0 1 (<0.1)
G8P[6] 1 (0.1) 0 0 0 0 1 (<0.1)
G8P[8] 0 (0.1) 1 0 1 (0.1) 0 2 (<0.1)
G8P[14] 1 0 (0.1) 1 (0.1) 0 0 2 (<0.1)
G10P[8] 0 0 (0.1) 1 (0.1) 0 0 1 (<0.1)
G12P[6] 1 (0.1) 0 0 3 (0.3) 0 4 (0.1)
Mixed infections b 16 (2.0) 12 (1.4) 5 (0.6) 10 (0.9) 21 (1.9) 64 (1.4)
Partially typed 0 4 (0.5) 4 (0.5) 18 (1.6) 40 (3.7) 66 (1.4)
a These strains are also included in mixed infections.
b Details on mixed infection strains are reported in the Supplementary material, Table S1.
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During the study period, 78 G12P[8] strains were detected with
a mean prevalence of 1.6% (0.0%e4.1%), of which 68 were detected
during the 2011e12 and 2012e13 seasons with 4.1% (n ¼ 35) and
3.0% (n¼ 33) prevalence, respectively. At the regional level, G12P[8]
strains emerged in 2011e12 at various rates in all regions except
Dijon and Charleville-Mezieres (see Supplementary material,
Fig. S3). They were still detected during the subsequent season in
only ﬁve cities (Brest, Lille, Paris, Poitiers and Saint-Etienne). VP7
phylogenetic analysis showed that all of these strains belonged to
lineage III and segregated into two relatively distinct main clusters
that differed from those of the older G12P[8] strains circulating in
France between 2005 and 2009, albeit, only three strains detected
in 2014 (R8391, R8422 and R8964) were more closely related to
these older G12P[8] strains (see Supplementary material, Fig. S4).
All G12P[8] strains harboured VP6 genes of human origin (genotype
I1). However, among these, two strains harboured NSP4 genes of
animal origin (genotype E2), whereas all of the others were of
human origin (genotype E1).
Human and animal reassortant rotaviruses
Forty (0.8%) atypical RVA strains, of which 27 (67.5%) were P[6]
strains, were detected during the surveillance and further charac-
terized according to their VP6 and NSP4 coding genes (see
Supplementary material, Table S3). Among these, 20 (51.3%) strains
bore genotypes commonly found in cattle: 13 (33.3%) G6, six
(15.4%) G8 and one (2.6%) G10 strains. Among the G8 strains, threewere combined with a major human P type: two with P[8] and one
with P[4] in three different locations and seasons. The single G10
strain was combined with P[8] and harboured VP6 and NSP4 genes
of human origin. Other strains were unusual combinations of
common G types with common human or potential zoonotic P
types such as P[3], P[6], P[9] and P[14].
Clinical characteristics and severity of rotavirus infections
Clinical records could be collected from 624 children who were
thereafter hospitalized in paediatrics departments. Comparisons of
clinical records in relation to genotypes are reported in Table 2. No
difference was found between RVA genotypes for the clinical pre-
sentation. None of the patients had been vaccinated. No deaths
were reported during the study period.
Vesikari severity scores could be calculated for 282 children
from the same cohort. In all, 148 (51.7%) infants, most of whom
were more than 6 months old (91.9%), hospitalized with rotavirus
gastroenteritis were classiﬁed as severe according to the Vesikari
scale (i.e. a score 11 points). Severity was signiﬁcantly lower in
children aged 0e6 months with a mean score of 8.9± 2.7 (p
<0.0001) than in the three other age groups. A linear regression
model using fractional polynomials was used to study this rela-
tionship, i.e. between the children’s age in months and the severity
score, and no linear relation was found (see Supplementary
material, Fig. S5). The mean Vesikari severity score of the 282
rotavirus infections was calculated at 10.30± 3.3 where G1P[8]
score was 10.24± 3.9 and G12P[8] score was 10.13± 2.8. No dif-
ference in Vesikari severity score was found between G1P[8], G2P
Table 2
Clinical characteristics according to rotavirus genotypes in 624 hospitalized diarrheal children between 2009 and 2014
G1P[8] G2P[4] G3P[8] G4P[8] G9P[8] G12P[8] Total p value a p value b
n¼407 n¼59 n¼74 n¼5 n¼52 n¼27 n¼624
Prevalence 64.2% 9.3% 11.7% 0.8% 8.2% 4.3% 100% d d
Mean age, months 14.2± 11.0 15.6± 13.4 15.6± 11.9 17.5± 15.6 11.9± 8.8 15.5± 11.2 14.3± 11.0 0.512 d 0.675 d
Sex ratio 1.6 1.3 1.3 0.7 2.5 1.8 1.6 0.520 e 0.495 e
Diarrhoea 93.9% 94.9% 97.3% 100.0% 96.2% 96.0% 94.7% 0.607 e 0.962 e
Mean number of diarrhoea bouts per day 6.0± 3.9 4.5± 3.0 8.3± 5.9 6.4± 5.9 7.5± 3.3 5.9± 5.8 6.4± 4.3 0.433 d 0.078 d
Vomiting 80.0% 84.7% 89.0% 100.0% 78.8% 80.0% 81.4% 0.575 e 0.498 e
Mean number of vomiting bouts per day 4.6± 3.4 5.3± 5.5 6.1± 4.0 2.5± 0.7 5.8± 5.2 7.7± 6.3 5.1± 4.2 0.114 d 0.516 d
Blood in stool 1.2% 0.0% 0.0% 0.0% 0.0% 4.0% 1.0% 0.306 e 0.464 e
Fever >38.5C 72.3% 73.9% 61.0% 75.0% 64.3% 77.8% 70.5% 0.349 e 0.361 e
Temperature, C 38.5± 1.0 38.6± 0.9 38.3± 1.0 38.4± 0.1 38.3± 0.8 38.5± 0.9 38.5± 0.9 0.719 d 0.308 d
Dehydration 54.7% 53.4% 75.7% 40.0% 65.4% 56.0% 57.7% 0.139 e 0.131 e
Dehydration degree, % 7.2± 3.5 6.0± 2.5 7.0± 3.4 3.5± 2.1 6.6± 3.6 6.4± 2.8 6.9± 3.4 0.545 d 0.223 d
Hypovolaemia 37.9% 25.9% 64.8% 20.0% 46.0% 54.2% 41.0% 0.345 e 0.158 e
Intravenous rehydration 61.2% 65.5% 74.3% 40.0% 60.8% 68.0% 63.2% 0.337 e 0.265 e
Oral rehydration 13.6% 19.0% 12.2% 20.0% 21.6% 12.0% 14.4% 0.553 e 0.402 e
Intensive care 1.2% 1.7% 2.7% 0.0% 1.9% 0.0% 1.4% 0.740 e 0.628 e
Hospitalization duration, days 2.8± 1.7 2.8± 1.6 2.7± 1.4 1.8± 1.1 2.5± 1.5 3.2± 1.7 2.8± 1.6 0.372 d 0.550 d
c Comparison within all genotype groups.
a Comparison between G1P[8] and G12P[8] groups.
b Comparison between all genotype groups.
d Using KruskaleWallis test.
e Using Fisher’s exact-test; statistically signiﬁcant if p <0.05.
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and G12P[8] (p 0.813) or between P[4] (9.93± 2.9) and P[8]
(10.38± 3.4) RVA infections (p¼0.386).
Discussion
During this 5-year study, we have shown that G12P[8] RVA
strains have emerged in France during two consecutive seasons,
and conﬁrmed that RVA infection severity is not related to
genotype.
Although rotavirus infections in Europe have been reported to
occur with a geographical gradient of increasing incidence from the
southwest towards the north [14], at the country level, they seem to
spread more according to centrifugal progression from areas where
the population density is the highest towards the lowest. In France,
the winter rotavirus epidemics occurred globally 2 months earlier
in large cities than in smaller provincial cities, as previously re-
ported [15]. Indeed, high population densities in the large cities
facilitate contact between individuals and may therefore play a
substantial role in shifting the epidemic peak.
During the study, the circulation of the G1P[8] strain in France
was overall predominant and similar to that in the rest of the world
despite the unexpected transient emergence of new major geno-
types. This predominance may be due to the emergence of new
antigenic G1 variants appearing or disappearing alternately under
the inﬂuence of natural immune-pressure mechanisms [16].
Following their emergence in France, G9P[8] strains maintained
a relatively high incidence level [15], before strongly decreasing
during the current study period. Interestingly, this decline occurred
much later in France than in other European countries, where, after
emergence, the prevalence of G9P[8] strains progressively
decreased season after season [17]. However, during the last season
in France, high G9P[8] prevalence was observed again. To date,
there is no evidence of any particular environmental or immune
factors that could explain the long circulation of G9 strains or their
renewed circulation in French infants.
During the study, G2P[4] prevalence was markedly high during
the 2009e10 season, but it was negligible in the rest of the study
period. These ﬂuctuations reﬂect the normal interseasonal diversity
of strains driven by the re-emergence of VP7 antigenic mutants, ormay be potentially due to reassortment among co-circulating
strains or an introduction of new lineages of G2 strains or antigen
combinations [18].
Whereas the detection rate for G4P[8] was relatively negligible
during the study, the circulation of G3P[8] strains increased and
then stabilized at around 14%. This increased frequency was sup-
posedly at the expense of the decrease in the frequencies of G1P[8]
and G9P[8] [19,20], but could just be related to the re-emergence of
G3 antigenic mutants.
G12 strains, ﬁrst detected in France in 2004, were the most
frequent among the uncommon strains detected in Europe and
Australia [17,21]. Recently, G12P[8] have emerged during the
2011e12 season in 11 of the 13 monitored regions but were only
persistent in ﬁve regions during the subsequent season. This
particularly mild emergence may be explained by both a herd im-
munity against P[8] types and an acquired cross-reactive immunity
of the population. Indeed, it differs from the intense emergence
reported in the north of Spain during the 2010e11 season [22],
although it could be related as the two countries share the same
borders and the Spanish G12 emergence preceded the French one
by only one season. Phylogenetically, these G12 strains belong to
lineage III but diverge from the older strains previously detected,
suggesting that an evolution of VP7 antigens or an introduction of
new strains in the country has occurred.
Infections with viruses of possible zoonotic origin was regularly
observed during the ﬁve seasons, notably G6 and G8 strains asso-
ciated with P[6] or P[14], which harboured NSP4 and VP6 genes
from porcine and bovine hosts, and might have resulted from
natural reassortment during animalehuman transmissions or
mixed human rotavirus infections from environmental reservoirs
[23,24]. These observations demonstrate the interspecies trans-
mission of RVAs, notably from animals living in close contact with
humans, resulting in the introduction of new rotavirus genotypes in
humans. Interestingly, two G8P[8] and one G8P[4] strains were
detected in three different places showing that some G8 strains
might initiate their adaption to humans, as previously observed for
G4, G9 and G12 strains. While the G8P[4] strainwas associatedwith
animal VP6 and NSP4 and was seemingly related to African strains
[25], both G8P[8] strains harboured human VP6 and NSP4 genes,
hence showing active recombination with human P[8] strains, as
A. de Rougemont et al. / Clinical Microbiology and Infection 22 (2016) 737.e9e737.e15737.e14previously reported [26]. These human G8P[8] strains require
further investigations to evaluate their potential emergence; their
ﬁtness is currently insufﬁcient to allow easy transmission to
humans.
Analysis of the clinical records showed no difference in clinical
manifestations or severity in relation to genotype. These results are
consistent with our previous ﬁndings [15,27]. More than half of the
rotavirus infections in these children were considered severe,
which is consistent with previous studies [28,29]. RVA infections in
children <6 months old were, however, less severe than those in
any other age group, probably thanks to the protection provided by
maternal antibodies. Commonly, differences in severity may be
explained by variations in virulence between strains and by the
immune status of the population towards a serotype, which is
partially dependent upon the infecting strain. However, globally,
most studies on rotavirus infection severity have been either
inconclusive or contradictory [27,30e32]. Nevertheless, both VP7
and VP4 antigens induce antibodies, and most of the genotypes
compared had the same P[8] type, thus abrogating the differences
between G types. As the severity of the disease does not depend on
age but on the infecting virus and previous exposure [33], severe
infections may be found mostly during primary infection or expo-
sure to new antigens, whereas less severe infections occur after
second exposure, during which heterotypic protection may reduce
the symptoms and shorten the infection. These data therefore
suggest that VP4 and VP7 antigens are not the only factors
responsible for the severity of rotavirus infections. Other strain-
speciﬁc viral factors and immune status, whether naive or after
previous infections, inﬂuence the intensity and the severity of the
clinical symptoms. The data also strongly suggest that all RVA ge-
notypes may cause acute gastroenteritis, as their G and P types
cannot be dissociated, and so reinforce the need for vaccines that
ensure effective protection, whether directly or by cross-reaction,
against all rotavirus infections.
Today, rotavirus vaccination is still too low in France to have any
impact on annual epidemics other than locally. The relative stability
of RVA genotypes currently co-circulating and the large predomi-
nance of P[8] type strains may ensure vaccine effectiveness, and,
given the good outcomes of vaccination in countries with sufﬁcient
coverage [34], extensive vaccination should be encouraged in France.
The surveillance of rotavirus infections during ongoing and future
vaccination programmes will ensure the detection of emergent new
reassortants and will help the health authorities to optimize
appropriate vaccination strategies against rotavirus diseases, all the
more so as all genotypes can cause severe infections in infants.
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Appendix 1. GenBank accession numbers
RVA/Human-wt/FRA/Lyon-R5957/2012/G12P[8]: KU291317, RVA/
Human-wt/FRA/Poitiers-R5485/2012/G12P[8]: KU291318, RVA/Human-wt/FRA/Limoges-R6183/2012/G12P[8]: KU291319, RVA/
Human-wt/FRA/Saint-Etienne-R6834/2013/G12P[8]: KU291320,
RVA/Human-wt/FRA/Saint-Etienne-R6784/2013/G12P[8]: KU291321,
RVA/Human-wt/FRA/Montpellier-R5396/2012/G12P[8]: KU291322,
RVA/Human-wt/FRA/Orleans-R7653/2013/G12P[8]: KU291323, RVA/
Human-wt/FRA/Montpellier-R7934/2014/G12P[8]: KU291324, RVA/
Human-wt/FRA/Paris-R7590/2013/G12P[8]: KU291325, RVA/
Human-wt/FRA/Caen-R6761/2013/G12P[8]: KU291326, RVA/Human-
wt/FRA/Paris-R7128/2013/G12P[6]: KU291327, RVA/Human-wt/FRA/
Paris-R6766/2013/G12P[8]: KU291328, RVA/Human-wt/FRA/Paris-
R8857/2014/G12P[8]: KU291329, RVA/Human-wt/FRA/Orleans-
R6110/2012/G12P[8]: KU291330, RVA/Human-wt/FRA/Paris-R6296/
2012/G12P[8]: KU291331, RVA/Human-wt/FRA/Caen-R6679/2012/
G12P[8]: KU291332, RVA/Human-wt/FRA/Paris-R7151/2013/G12P
[8]: KU291333, RVA/Human-wt/FRA/Poitiers-R6940/2013/G12P[8]:
KU291334, RVA/Human-wt/FRA/Brest-R6975/2013/G12P[8]:
KU291335, RVA/Human-wt/FRA/Saint-Etienne-R8964/2014/G12P[8]:
KU291336, RVA/Human-wt/FRA/Saint-Etienne-R1725/2007/G12P[6]:
KU291337, RVA/Human-wt/FRA/Brest-R8391/2014/G12P[8]: KU291
338, RVA/Human-wt/FRA/Brest-R8422/2014/G12P[8]: KU291339,
RVA/Human-wt/FRA/Brest-R5875/2012/G12P[8]: KU291340, RVA/
Human-wt/FRA/Lyon-R5790/2012/G12P[8]: KU291341, RVA/Human-
wt/FRA/Lille-R5374/2012/G12P[8]: KU291342, RVA/Human-wt/FRA/
Lille-R6147/2012/G12P[8]: KU291343, RVA/Human-wt/FRA/Lille-
R5373/2012/G12P[8]: KU291344, RVA/Human-wt/FRA/Saint-
Etienne-R5462/2012/G12P[8]: KU291345, RVA/Human-wt/FRA/
Caen-R6642/2012/G12P[8]: KU291346, RVA/Human-wt/FRA/Rennes-
R5533/2012/G12P[8]: KU291347, RVA/Human-wt/FRA/Rennes-
R5506/2012/G12P[8]: KU291348, RVA/Human-wt/FRA/Rennes-
R5510/2012/G12P[8]: KU291349, RVA/Human-wt/FRA/Lyon-R5615/
2012/G12P[8]: HF952916, RVA/Human-wt/FRA/Saint-Etienne-
R4925/2011/G12P[8]: HF952915, RVA/Human-wt/FRA/Paris-R4380/
2010/G12P[6]: HF952913 and RVA/Human-wt/FRA/Dijon-R4969/
2011/G12P[8]: HF952914.
Appendix A. Supporting information
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.cmi.2016.05.025.
References
[1] Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, et al. 2008
estimate of worldwide rotavirus-associated mortality in children younger
than 5 years before the introduction of universal rotavirus vaccination pro-
grammes: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:
136e41.
[2] Trojnar E, Sachsenroder J, Twardziok S, Reetz J, Otto PH, Johne R. Identiﬁcation
of an avian group A rotavirus containing a novel VP4 gene with a close
relationship to those of mammalian rotaviruses. J Gen Virol 2013;94:136e42.
[3] Matthijnssens J, De Grazia S, Piessens J, Heylen E, Zeller M, Giammanco GM,
et al. Multiple reassortment and interspecies transmission events contribute
to the diversity of feline, canine and feline/canine-like human group A rota-
virus strains. Infect Genet Evol 2011;11:1396e406.
[4] Iturriza-Gomara M, Dallman T, Banyai K, Bottiger B, Buesa J, Diedrich S, et al.
Rotavirus genotypes co-circulating in Europe between 2006 and 2009 as
determined by EuroRotaNet, a pan-European collaborative strain surveillance
network. Epidemiol Infect 2011;139:895e909.
[5] Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and
its implication for the development and implementation of an effective
rotavirus vaccine. Rev Med Virol 2005;15:29e56.
[6] Todd S, Page NA, Duncan Steele A, Peenze I, Cunliffe NA. Rotavirus strain types
circulating in Africa: review of studies published during 1997e2006. J Infect
Dis 2010;202(Suppl):S34e42.
[7] Matthijnssens J, Bilcke J, Ciarlet M, Martella V, Banyai K, Rahman M, et al.
Rotavirus disease and vaccination: impact on genotype diversity. Future
Microbiol 2009;4:1303e16.
[8] Ciarlet M, Hoshino Y, Liprandi F. Single point mutations may affect the sero-
type reactivity of serotype G11 porcine rotavirus strains: a widening spec-
trum? J Virol 1997;71:8213e20.
[9] Melliez H, Boelle PY, Baron S, Mouton Y, Yazdanpanah Y. [Morbidity and cost
of rotavirus infections in France]. Med Mal Infect 2005;35:492e9.
A. de Rougemont et al. / Clinical Microbiology and Infection 22 (2016) 737.e9e737.e15 737.e15[10] Martinot A, Cohen R, Denis F, Gaudelus J, Lery T, Lepetit H, et al. [Assessing
early childhood vaccination coverage in France after 2013 vaccination
schedule implementation]. Arch Pediatr 2014;21:1389e90.
[11] Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical
scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990;22:
259e67.
[12] Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular
Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 2013;30:2725e9.
[13] Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high
throughput. Nucleic Acids Res 2004;32:1792e7.
[14] Koopmans M, Brown D. Seasonality and diversity of Group A rotaviruses in
Europe. Acta Paediatr Suppl 1999;88:14e9.
[15] de Rougemont A, Kaplon J, Pillet S, Mory O, Gagneur A, Minoui-Tran A, et al.
Molecular and clinical characterization of rotavirus from diarrheal infants
admitted to pediatric emergency units in france. Pediatr Infect Dis J 2011;30:
118e24.
[16] Arista S, Giammanco GM, De Grazia S, Ramirez S, Lo Biundo C, Colomba C,
et al. Heterogeneity and temporal dynamics of evolution of G1 human rota-
viruses in a settled population. J Virol 2006;80:10724e33.
[17] Iturriza-Gomara M, Dallman T, Banyai K, Bottiger B, Buesa J, Diedrich S, et al.
Rotavirus surveillance in Europe, 2005e2008: web-enabled reporting and
real-time analysis of genotyping and epidemiological data. J Infect Dis
2009;200(Suppl 1):S215e21.
[18] Wu FT, Banyai K, Jiang B, Wu CY, Chen HC, Feher E, et al. Molecular epide-
miology of human G2P[4] rotaviruses in Taiwan, 2004e2011. Infect Genet
Evol 2014;28:530e6.
[19] Stupka JA, Degiuseppe JI, Parra GI. Argentinean National Rotavirus Surveil-
lance N. Increased frequency of rotavirus G3P[8] and G12P[8] in Argentina
during 2008e2009: whole-genome characterization of emerging G12P[8]
strains. J Clin Virol 2012;54:162e7.
[20] Mitui MT, Chan PK, Nelson EA, Leung TF, Nishizono A, Ahmed K. Co-domi-
nance of G1 and emerging G3 rotaviruses in Hong Kong: a three-year sur-
veillance in three major hospitals. J Clin Virol 2011;50:325e33.
[21] Kirkwood CD, Boniface K, Bogdanovic-Sakran N, Masendycz P, Barnes GL,
Bishop RF. Rotavirus strain surveillance e an Australian perspective of strains
causing disease in hospitalised children from 1997 to 2007. Vaccine
2009;27(Suppl 5):F102e7.
[22] Cilla G, Montes M, Gomariz M, Alkorta M, Iturzaeta A, Perez-Yarza EG, et al.
Rotavirus genotypes in children in the Basque Country (North of Spain): rapid
and intense emergence of the G12[P8] genotype. Epidemiol Infect 2013;141:
868e74.
[23] Rahman M, De Leener K, Goegebuer T, Wollants E, Van der Donck I, Van
Hoovels L, et al. Genetic characterization of a novel, naturally occurring re-
combinant human G6P[6] rotavirus. J Clin Microbiol 2003;41:2088e95.[24] Cunliffe NA, Gentsch JR, Kirkwood CD, Gondwe JS, Dove W, Nakagomi O,
et al. Molecular and serologic characterization of novel serotype G8 hu-
man rotavirus strains detected in Blantyre, Malawi. Virology 2000;274:
309e20.
[25] Nyaga MM, Stucker KM, Esona MD, Jere KC, Mwinyi B, Shonhai A, et al.
Whole-genome analyses of DS-1-like human G2P[4] and G8P[4] rotavirus
strains from Eastern, Western and Southern Africa. Virus Genes 2014;49:
196e207.
[26] Delogu R, Lo Presti A, Ruggeri FM, Cella E, Giovanetti M, Ciccozzi M, et al. Full-
genome characterization of a G8P[8] rotavirus that emerged among children
with diarrhea in Croatia in 2006. J Clin Microbiol 2013;51:1583e8.
[27] Aupiais C, de Rougemont A, Menager C, Vallet C, Brasme JF, Kaplon J, et al.
Severity of acute gastroenteritis in infants infected by G1 or G9 rotaviruses.
J Clin Virol 2009;46:282e5.
[28] Matthijnssens J, Zeller M, Heylen E, De Coster S, Vercauteren J, Braeckman T,
et al. Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases
compared with unvaccinated hospitalized cases, despite high vaccine effec-
tiveness against heterotypic G2P[4] rotaviruses. Clin Microbiol Infect 2014;20:
O702e10.
[29] Lewis KD, Dallas MJ, Victor JC, Ciarlet M, Mast TC, Ji M, et al. Comparison of
two clinical severity scoring systems in two multi-center, developing country
rotavirus vaccine trials in Africa and Asia. Vaccine 2012;30(Suppl. 1):
A159e66.
[30] Cascio A, Vizzi E, Alaimo C, Arista S. Rotavirus gastroenteritis in Italian chil-
dren: can severity of symptoms be related to the infecting virus? Clin Infect
Dis 2001;32:1126e32.
[31] Linhares AC, Verstraeten T, Wolleswinkel-van den Bosch J, Clemens R,
Breuer T. Rotavirus serotype G9 is associated with more-severe disease in
Latin America. Clin Infect Dis 2006;43:312e4.
[32] Clark HF, Lawley DA, Schaffer A, Patacsil JM, Marcello AE, Glass RI, et al.
Assessment of the epidemic potential of a new strain of rotavirus associated
with the novel G9 serotype which caused an outbreak in the United States
for the ﬁrst time in the 1995e1996 season. J Clin Microbiol 2004;42:
1434e8.
[33] Albano F, Bruzzese E, Bella A, Cascio A, Titone L, Arista S, et al. Rotavirus and
not age determines gastroenteritis severity in children: a hospital-based
study. Eur J Pediatr 2007;166:241e7.
[34] Leshem E, Moritz RE, Curns AT, Zhou F, Tate JE, Lopman BA, et al. Rotavirus
vaccines and health care utilization for diarrhea in the United States
(2007e2011). Pediatrics 2014;134:15e23.
[35] de Rougemont A, Kaplon J, Lebon P, Huet F, Denis F, Alain S, et al. Unexpected
substitution of dominant rotavirus G genotypes in French hospitalized chil-
dren over ﬁve consecutive seasons. Eur J Clin Microbiol Infect Dis 2009;28:
403e7.
